Research Progress on the Pharmacological Action of Schisantherin A | Zendy

Zehao Xiao | Zendy; Wen Xiao | Zendy; Guilin Li | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Research Progress on the Pharmacological Action of Schisantherin A

Author(s) -

Zehao Xiao,

Wen Xiao,

Guilin Li

Publication year - 2022

Publication title -

evidence-based complementary and alternative medicine

Language(s) - English

Resource type - Journals

eISSN - 1741-4288

pISSN - 1741-427X

DOI - 10.1155/2022/6420865

Subject(s) - schisandra chinensis , protein kinase b , pi3k/akt/mtor pathway , mapk/erk pathway , pharmacology , chemistry , mechanism of action , lignan , apoptosis , schisandra , traditional medicine , medicine , signal transduction , biochemistry , traditional chinese medicine , stereochemistry , in vitro , alternative medicine , pathology

Schisantherin A (Sch A) is a dibenzocyclooctadiene lignan monomer isolated from the fruit of Schisandra chinensis (Turcz.) Baill. (S. chinensis). At present, many studies have shown that Sch A has a wide range of pharmacological effects, including its anti-Parkinson and anti-inflammatory effects and ability to protect the liver, protect against ischemia-reperfusion (I/R) injury, suppress osteoclast formation, and improve learning and memory. Its mechanism may be related to the antioxidant, anti-inflammatory, and antiapoptotic properties of Sch A through the MAPK, NF-κB, AKT/GSK3β, and PI3K/AKT pathways. This is the first review of the recent studies on the pharmacological mechanism of Sch A.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research